Loading stock data…
BioLife Solutions, Inc. (BLFS)
$28.30-0.37 (-1.29%)
After Hours$28.30+0.00 (+0.00%)· Last close Jun 29
BioLife Solutions, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioLife Solutions, Inc. in the Healthcare sector is trading at $28.30 with a market capitalization of $1.3B. Wall Street consensus targets $32.11 (9 analysts), implying a +13.5% move over the next 12 months. The stock is currently near its 52-week high of $30.00, remaining 18.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +13.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $27.50M↑ | $18.79M↓ | $28.07M↑ | $25.42M↑ | $22.05M |
| Gross Profit | $17.50M↑ | $11.98M↓ | $17.92M↑ | $16.43M↑ | $14.80M |
| Operating Income | $27,000↓ | $1.35M↑ | -$89,000↑ | -$16.64M↓ | -$499,000 |
| Net Income | $1.19M↓ | $11.07M↑ | $621,000↑ | -$15.84M↓ | -$448,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.80%
Volume
Today's trading volume
3.39M
Recent News
What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?
Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared to the Russell 2000 Index’s +0.9% return and the HFRX Equity Hedge Index’s -1.5% return. Long book performance […]
BioLife Solutions Leads 3 Stocks Estimated To Be Trading Below Fair Value
The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
Orthofix Medical and 5 More Stocks See Action From Activist Investors
Activists also report to the SEC on BioLife Solutions, Garrett Motion, Life Time Group Holdings, Infleqtion, and CBL Properties.
A Look At BioLife Solutions (BLFS) Valuation As Shares Show Recent Short Term Momentum
Why BioLife Solutions (BLFS) is on investors’ radar BioLife Solutions (BLFS) has drawn attention after recent share price moves, with the stock up about 21% over the past month and roughly 3% in the past 3 months. For investors tracking the cell and gene therapy supply chain, these returns, together with annual revenue of US$96.2 million and a reported net loss of US$12.13 million, raise questions about how the stock is being valued today. See our latest analysis for BioLife Solutions. At a...
BioLife (BLFS) Q1 2026 Earnings Transcript
Good afternoon, everyone, and thank you for joining us for BioLife's First Quarter 2026 Conference Call. Performance in the quarter was driven by continued strength across our broader product portfolio, led by our biopreservation media or BPM franchise. At the same time, we're seeing continued momentum across the CGT landscape, driven by expansion into larger indications, encouraging data readouts, strategic M&A and an improving funding environment, all of which we believe will support long-term growth across our end markets and underpins sustained value creation for BioLife shareholders.